facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
2/2022
vol. 109
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
List do Redakcji

Świerzbiączka guzkowa leczona dożylnie immunoglobulinami

Koray Durmaz
1
,
Arzu Ataseven
2
,
Ilkay Ozer
2
,
Sıddıka Fındık
3

  1. Yasam Hospital Clinic of Dermatology, Kirikkale, Turkey
  2. Department of Dermatology, Faculty of Medicine, Necmettin Erbakan University Meram, Konya, Turkey
  3. Department of Pathology, Faculty of Medicine, Necmettin Erbakan University Meram, Konya, Turkey
Dermatol Rev/Przegl Dermatol 2022, 109, 159-162
Data publikacji online: 2022/07/08
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Prurigo nodularis is a chronic skin disease, especially seen in middle-aged women adults. It is characterized by symmetric, pruritic hyperkeratotic nodules and papules on the extensor surfaces [1]. Prurigo nodularis patients can suffer from repeated itching and scratching cycles or intensive pruritus. The etiology of prurigo nodularis is not clear. The lesions can be seen primarily or be caused by another pruritic condition. The trigger can be other dermatoses such as atopic dermatitis or secondary pruritus due to another systemic disease such as chronic kidney disease, jaundice, malignancies, etc. The interaction between cutaneous nerve fibers and immune cells can play a crucial role in pathogenesis [2]. Treatment options for prurigo nodularis are limited by studies. Most of the studies aim at symptomatic relief of patients [3].


© 2024 Termedia Sp. z o.o.
Developed by Bentus.